Amgen announced yesterday that it will acquire apremilast (Otezla) from Celgene. The small-molecule drug, which inhibits phosphodiesterase 4, specific for cyclic adenosine monophosphate, is an orally administered therapy for patients with psoriatic arthritis and patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Amgen announced yesterday that it will acquire apremilast (Otezla) from Celgene. The small-molecule drug, which inhibits phosphodiesterase 4, specific for cyclic adenosine monophosphate, is an orally administered therapy for patients with psoriatic arthritis (PsA) and patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Celgene’s sale of the drug, for which Amgen is to pay $13.4 billion in cash, or approximately $11.2 billion net of the present value of $2.2 billion in anticipated future cash tax benefits, is in connection with Celgene’s merger with Bristol-Myers Squibb.
In 2018, apremilast was responsible for $1.6 billion in sales for Celgene, and Amgen has indicated that it believes it has an opportunity to deliver double-digit sales growth over the coming 5 years through new indications and through global expansion. Additionally, the drug will retain its exclusivity through 2028.
Robert Bradway, chairman and chief executive officer of Amgen, said in a statement that the acquisition of an oral therapy for psoriasis and PsA “fits squarely within our portfolio” of brands, including brand-name etanercept (Enbrel) and biosimilar adalimumab (Amgevita), which has already launched in the European Union and will launch in the United States as Amjevita in 2023.
“We will take advantage of our 20 years of experience in inflammatory disease to realize the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions,” added Bradway.
The acquisition of the drug, which will be contingent on Bristol-Myers Squibb entering into a consent decree with the Federal Trade Commission in connection with its proposed merger with Celgene, is expected to close by the end of the year.
Bringing apremilast onboard could help Amgen to mitigate the effects of eventual biosimilar competition for etanercept, which also treats psoriasis and PsA, in the United States. To date, 2 biosimilars referencing Enbrel are approved in the United States: Sandoz’s Erelzi and Samsung Bioepis’ Eticovo. Neither of the drugs has launched, however, although etanercept biosimilars are available in other highly regulated territories.
Recently, a US court sided with Amgen in a long-running patent dispute with Sandoz over etanercept, potentially keeping biosimilar competition at bay until 2029. However, Sandoz plans to appeal the decision, and if the court sides with Sandoz, biosimilar competition for the blockbuster Enbrel could begin in the United States much sooner.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.